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Background/aim: miRNAs control various biological functions, such as cell proliferation, differentiation, signaling pathways, apoptosis
and metabolism. Recently, it has been shown that there is a relationship between changes in miRNA expression and the development of
acromegaly. Studies are needed to identify new disease-specific miRNAs. The aim of the current study is to evaluate plasma miR-29c-3p,
miR-31-5p and miR-18a-5p steady-state levels in acromegaly. Another aim is to investigate whether there is a difference in the levels of
these miRNAs in patients with inadequate control and controlled acromegaly with somatostatin analog (SSA) therapy. These miRNAs
targeting the IGF-1 gene were determined by in silico estimation.
Materials and methods: The study included 30 healthy controls (HC) and 20 patients with acromegaly. Anterior pituitary functions and
disease activities of patients with acromegaly were evaluated at the time of study. The miR-29c-3p, miR-31-5p and miR-18a-5p levels
were measured using quantitative real-time PCR (RT-qPCR).
Results: The expression level of miR-29c-3p was significantly lower in patients with acromegaly compared to the HC group (p < 0.001).
This downregulation was more pronounced in patients with inadequately controlled acromegaly than in patients with acromegaly
controlled with somatostatin analogues (SSA) therapy (p = 0.016). Univariate logistic regression analysis results showed that down
regulation of miR-29c-3p expression increases the risk of developing acromegaly [OR (95% Cl) = 1.605 (1.142-2.257), p = 0.006]. There
was no significant difference between the groups in terms of miR-31-5p and miR-18a-5p expression levels (p = 0.375 and p = 0.649,
respectively).
Conclusion: Plasma miR-29c-3p expression level is downregulated in patients with acromegaly, and this is more pronounced in patients
with inadequate control.
Key words: Acromegaly, miR-29c-3p, miR-31-5p, miR-18a-5p

1. Introduction
Acromegaly is an endocrine disease that usually originates
from the somatotropic cells of the pituitary gland and
causes the release of excess growth hormone (GH) and
insulin-like growth factor 1 (IGF-1). Increased IGF-1
levels stimulate cell proliferation and inhibit apoptosis [1].
Increasing evidence has shown that miRNAs play a
role in the pathophysiology of GH-secreting pituitary
adenoma. Studies found that GH-secreting pituitary
adenoma samples have downregulations or upregulations
in the expression of various miRNAs compared to normal
pituitary tissues, and some of them are associated with
proliferation, migration and invasion of tumor cells [2,3].
miRNAs are used as potential circulating biomarkers for
the diagnosis and prognosis of many diseases due to their
stable structure and detectability in plasma [4]. GH and

IGF-1 levels are used as biomarkers in the diagnosis and
follow-up of acromegaly [5].
It is thought that circulating miRNAs may be useful
in predicting the prognosis of patients with acromegaly
and their response to treatment with somatostatin analogs
(SSAs) [3,6]. New studies are needed to identify specific
circulating miRNAs for acromegaly disease.
In this study, miRNAs targeting the IGF-1 gene were
determined by in silico estimation. For this purpose, miRDB
(http://mirdb.org/index.html) and TargetSan Release 7.2
(http://www.targetscan.org/vert_72/) algorithms were
used and miR-31-5p, miR-18a-5p and miR-29c-3p were
determined as candidate miRNAs. miR-29c-3p and miR31 are tumor suppressor miRNAs. Downregulations of
these miRNAs were associated with development and
poor prognosis of various tumors [7–10]. Different tumor
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studies have shown that miR-18a has both oncogenic
and tumor suppressive roles. It was thought that the dual
functional of miR-18a may be attributed to fundamental
differences in tumorigenic mechanisms [11–13]. These
miRNAs, which have been proven to be associated with
various malignancies, were not evaluated in patients with
acromegaly to date.
The primary aim of the current study is to evaluate
whether there is a difference in plasma miR-29c-3p,
miR-31-5p and miR-18a-5p expression levels in patients
with acromegaly compared to healthy controls (HCs).
The second aim is to compare these miRNAs in patients
with inadequately controlled acromegaly and acromegaly
controlled with SSA therapy.
2. Material and methods
This study was conducted according to the principles of
the Helsinki Declaration after it was approved by the local
ethics committee. All participants were informed about
the research protocol, and they declared their voluntary
attendance by signed written consent.
2.1. Selection of samples
Twenty patients with acromegaly (mean age 53.15 ±
11.5 years, 10 females, 10 males) and 30 healthy controls
(mean age 54.5 ± 8 years, 13 females and 17 males) were
included in the study. In patients with acromegaly, those
with infectious diseases, rheumatic diseases, pulmonary
diseases, liver failure, kidney failure, pregnancy, and
different malignancy apart from acromegaly were
excluded from the study. Age and sex matched HC group
was randomly selected from people without any systemic
disease and drug use.
Disease durations, medical history (medical,
surgical, and surgery), treatment response evaluations,
demographic features, comorbid conditions, treatment
histories (surgery, radiotherapy, pharmacological therapy),
pituitary functions, and medical histories were recorded.
Controlled acromegaly was defined as random GH level,
which was below 1.0 ng/mL, and IGF-1 values were in the
reference range for age and sex. Inadequately controlled
acromegaly was defined as mean GH >2.5 μg/L and IGF-1
>1.3 times the sex- and age-adjusted upper limit of normal
(ULN). In this study, 7 of the patients with acromegaly
consisted of inadequately controlled patients.
All of the patients included in the study underwent
transsphenoidal pituitary surgery and were still receiving
SSA therapy. There were no patients who received SSA
treatment before transsphenoidal pituitary surgery.
Eight patients required treatment for some degree of
hypopituitarism, namely with L-thyroxine, hydrocortisone
and/or gonadal steroids. All patients with hypothyroidism
were receiving adequate hormone replacement.
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2.2. Biochemical analysis
After at least 8 h of fasting, 5 cc peripheral venous blood
samples were collected into three blood collection tubes (2
EDTA-containing and 1 gel-included biochemistry tubes)
from all participants.
Serum fasting blood glucose (FBG), alanine
aminotransaminase (ALT), creatinine, uric acid, total
cholesterol (TC), triglyceride (TG), and high-density
lipoprotein cholesterol (HDL-C) were measured using a
Beckman Coulter AU 5800 chemistry analyzer (Beckman
Coulter, Brea, CA, USA). Low-density lipoprotein
cholesterol (LDL-C) was calculated with the Friedewal
formula [LDL-C= TC - (HDL-C+ (TG/5)].
Serum IGF-1 and GH levels were measured by electrochemiluminescence immunoassay (Elecsys IGF-1; Roche
Diagnostics, Mannheim, Germany). The normal range of
serum IGF-1 was evaluated by sex and age. Age and sexnormalized levels of IGF-1, rare GH< 0.4 ng/mL in oral
glucose tolerance test (OGTT) after surgery and random
GH<1 ng/mL when treating with SSA were accepted
criteria for cure or good biochemical control [14].
2.3. miRNA extraction, primer design
Extraction of microRNAs was carried out using a peripheral
blood plasma sample with the Hybrid-RTM miRNA
isolation kit (GeneAll Biotechnology, Korea). The purity and
concentration of these microRNAs were measured using
an ultraviolet spectrophotometer at 260 nm and 280 nm
absorption using a Nanodrop spectrophotometer Thermo
Fisher Qubit 3.0 (Thermo Fisher Scientific Inc.,Waltham,
MA, USA). The microRNA was then stored at –80 °C up
to the cDNA synthesis stage. NCBI (National Center for
Biotechnology Information) nucleotide database was used
for primer sequences of miRNAs.
The sequence used for miR-29c-3p includes primers as
follows: Forward: 5’- TAGCACCATTTGAAATCGGTTA3´(Accession No: MIMAT0000681). For miR-315p:
Forward:
5’-AGGCAAGATGCTGGCATAGCT3’(Accession No: MIMAT0000089). For miR-18a-5p:
5’-TAAGGTGCATCTAGTGCAGATAG-3’(Accession
No: MIMAT0000072), while U6 snRNA as housekeeping
gene includes primers as follows: Forward: 5’GCTTCGGCAGCACATATACTAAAAT -3´.
2.4. cDNA synthesis and RT-PCR measurement
Complementary DNA (cDNA) was obtained from the
isolated miRNAs using the HyperScriptTM Reverse
Transcriptase kit (GeneAll Biotechnology, Korea). Reverse
transcription was performed using SimpliAmp Thermal
Cycler (Waltham, MA, USA). Quantitative real-time PCR
reactions (qRT-PCR) were performed with the highcapacity StepOnePlus real-time PCR System (Waltham,
MA, USA). The thermal cycling conditions were as follows:
an initial denaturation step at 95 ℃ for 10 min, 40 cycles
of PCR amplification at 95 ℃ for 15 s, and 60 ℃ for 1 min,
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followed by a melting curve analysis program according
to the instrument documentation. All real-time PCR
reactions were run in triplicate. The sequences of all the
primers used are listed in Table 1. The expression levels of
miR-29c, miR-31, and miR-18a were examined using the
real-time PCR technique and the SYBER Green method,
using U6 snRNA as an internal control (housekeeping
gene). The cycle threshold (CT) of investigated primers
was determined and normalized to the housekeeping
gene, RNU6. Fold change of each miRNA expression was
calculated using the equation 2−ΔΔCt.
2.5. Statistical analysis
SPSS for Windows version 22.0 (IBM Corp., Armonk, NY,
USA) was used for statistical analysis. For the comparison
of categorical data, a chi-square test (sex) was used. After
the Kolmogorov–Smirnov test, the normal distribution
parameters (age, HDL-C, LDL-C and TC) were compared
with the Student’s t test, and parameters with non-normal
distribution were compared using the Mann–Whitney
U test. miR-29c-3p expression levels of inadequately
controlled and controlled acromegaly patients with SSA
therapy were compared by using the Mann–Whitney U test.
To evaluate the relationship between parameters, Pearson
correlation analysis was used for those with parametric
distribution, and Spearman correlation analysis was used
for those with non-parametric distribution. The effect of
miR-29c-3p expression on acromegaly development was
evaluated by univariate logistic regression analysis. The p
value <0.05 was considered statistically significant.
3. Results
The clinical and demographic characteristics of the groups
are shown in Table 1. There was no significant difference

in age and sex between HC and acromegaly groups. (p =
0.820 and p = 0.643, respectively). Laboratory features of
the groups are shown in Table 2. Fasting plasma glucose
(FBG) level was higher in patients with acromegaly than in
the HC group (p < 0.001). There was no difference between
the groups in terms of creatinine, alanine aminotransferase
(ALT) and lipid levels (for each, p > 0.05).
There was no significant difference between the groups
in terms of miR-31-5p and miR-18a expression levels (p =
0.375 and p = 0.649, respectively).
In patients with acromegaly, miR-29c-3p expression
was significantly downregulated compared to the HC
group (p < 0.001). Univariate logistic regression analysis
results demonstrated an important association between
acromegaly development and downregulation of miR29c-3p expression [OR (95% Cl) = 1.605 (1.142–2.257),
p = 0.006]. Average expression levels and fold changes of
miRNAs isolated from plasma are given in Figure 1 and
Table 2.
miR-29c-3p expression was downregulated in patients
with inadequately controlled acromegaly compared to
those controlled with SSA therapy (p = 0.016, Figure
2). There was no significant difference in miR-18a-5p
and miR-31-5p expression levels between patients with
inadequately controlled and controlled acromegaly with
SSA therapy (p = 0.427 and p = 0.571, respectively).
There was no correlation between plasma miR-29c-3p
and IGF-1 levels in patients with acromegaly.
4. Discussion
In the current study, the miR-29c-3p level was found to be
significantly lower in patients with acromegaly compared
to age- and sex-matched HC. In addition, the miR-29c-3p

Table 1. Demographic and clinical characteristics of patients with acromegaly and HCs.
Acromegaly

Healthy control

Sex (male/female)

10/10

17/13

Age (years)

53.15 ± 11.5

54.5 ± 8

Duration of diagnosis (years)

6±3

Somatostatin analog theraphy

n = 20

Inadequately controlled acromegaly

7/20

Contrelled acromegaly

13/20

Postoperative radiotheraphy

n=1

Hypopituitarism

n=4

ACTH deficiency

1/4

Gonodotropin deficiency

3/4

TSH deficiency

3/4

Datas expressed as mean ±SD and n. Adrenocorticotropic hormone, ACTH; thyroid stimulating
hormone, TSH.
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Table 2. Biochemical characteristics of of the groups.
Acromegaly

Healthy control

p

FBG (mg/dL)

113±38

93±11

<0.001

Creatinine (mg/dL)

0.97±0.19

0.83±0.25

0.086

ALT (U/L)

16±7

17±10

0.475

TC (mg/dL)*

198.5 (121-256)

2094 (151-293)

0.081

TG (mg/dL)

114±60

112±79

0.677

HDL-C (mg/dL)*

50 (34-67)

48.50 (31-85)

0.272

LDL-C (mg/dL)*

120 (76-189)

130.5 (86-183)

0.096

IGF-1 (ng/mL)

228.5±193

-

GH (ng/mL)

0.98±1.72

-

Exp re s s io n Le ve l (Fo ld Ch a n g e )

Datas expressed as *median (min-max) and mean (±SD). Fasting blood glucose, FBG;
alanine aminotransaminase, ALT; high-density lipoprotein cholesterol, HDL-C; low-density
lipoprotein cholesterol, LDL-C; triglyceride, TG; total cholesterol, TC; insulin-like growth
factor 1, IGF-1, growht hormone, GH.
1.2
1

Acromegaly

Control

0.8
0.6
0.4
0.2
0

miR-31

miR-18a

miR-29c-3p

Expressed miRNAs

Figure 1. Fold changes of miRNAs in patients with acromegaly and HCs.

expression level was lower in patients with inadequately
controlled acromegaly compared to patients controlled
with SSA therapy. To the best of our knowledge, this is the
first study to evaluate plasma miR-29c-3p expression levels
in patients with acromegaly.
There are limited number of studies evaluating
circulating miRNAs in patients with acromegaly. Valassi et
al. showed that changes in plasma miR-103a-3p and miR660-5p expressions were found in patients with acromegaly,
and these changes were related to both structural and
biochemical parameters of bone metabolism [15]. Zhao
et al. showed that exosome miR-423-5p and miR-320a
expression were lower in GH-secreting pituitary adenoma
than in normal pituitary tissue. They found that miR-4235p inhibits cell proliferation and migration, induces cell
apoptosis, and reduces GH release during an in-vitro study.
Researchers suggested that miR-423-5p plays a central role
in promoting tumor formation in somatotroph adenomas
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and may act as a potential biomarker for therapeutic
interventions using gene therapy [16]. Circulating miRNAs
can be a potentially useful diagnostic marker by improving
the classification of acromegaly. Therefore, new circulating
miRNAs specific to acromegaly should be identified.
In the current study, plasma miR-29c-3p expression
was evaluated in patients with acromegaly. miR-29c-3p is
a tumor suppressor and was found to be downregulated
in many malignant diseases. In addition, downregulation
of miR-29c-3p expression was shown to be associated
with lymph node metastasis, poorly differentiated tumor,
advanced TNM stage and poor prognosis [7,9,17]. In this
study, plasma miR-29c-3p expression was significantly
lower in patients with acromegaly compared to HCs.
The roles of miRNAs in the development of acromegaly
were evaluated by logistic regression analysis. The
downregulation of plasma miR-29c-3p was shown to
increase the risk of acromegaly 1.6 times.
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mi R- 29c- 3p rel ati ve expr es s i on l evel ( Fold Change)

1.00

18

0.80

0.60

0.40

0.20

0.00
Controlled Acromegaly

Uncontrolled Acromegaly

Figure 2. Fold changes of miR-29c-3p in patients with controlled
and uncontrolled acromegaly.

Transsphenoidal pituitary surgery is preferred for
first-line treatment in patients with acromegaly. Since
the remission rate of the disease after pituitary surgery
is 28%–39%, most of the patients with acromegaly need
additional treatment such as radiosurgery and medical
treatment. SSAs are widely used in the medical treatment
of acromegaly, but patient response to this treatment is
highly variable [18–21]. Predicting the medical treatment
response will be useful for determining the treatment plan
[3]. Therefore, there is a need to identify biomarkers that
may have a role in predicting treatment responses. Mao et
al. evaluated the relationship between response to SSA and
miRNAs expression levels after administering SSA therapy
to patients with GH secreting adenoma for 4 months
before the pituitary operation. They found that miR-5245p was downregulated patients who were SSA responders
compared to SSA nonresponders, and miR-524-5p was
upregulated after SSA treatment was discontinued.
Researchers suggested that determining target miRNAs
can be important in predicting the response to SSA
therapy in acromegaly [3]. In the current study, miR-29c3p expression was lower in patients with inadequately
controlled acromegaly than in patients controlled with
SSA therapy. miR-29c-3p may be an alternative biomarker

for predicting the SSA treatment response of patients with
acromegaly. However, whether miR-29c-3p had any role in
predicting the response to SSA therapy can be understood
with prospective studies in which more cases are included.
Such a possible relationship may be due to several reasons.
miR-2pc-3p is a miRNA that targets the IGF-1 gene (based
on in- silico evaluation) and may show effects at the hepatic
level. In addition, increased SST2 expression, dense tumor
granularity and low proliferative index (Ki-67) expression
in tumor tissue are histopathological findings showing that
the response to SSA treatment will be better [22]. miR29c-3p expression levels may also be associated with these
histopathological findings. There is a need for advanced
molecular studies at tissue level on this subject.
This study has some limitations. The first is that it is a
cross-sectional study, so no information about causality can
be provided. Secondly, the number of samples is relatively
low. However, it is difficult to reach large study groups as
acromegaly is a rare disease. In addition, the fact that this
study did not evaluate the histopathological findings in
tumor tissue and the relationships between these miRNAs
is another limitation.
In conclusion, expression of miR-29c-3p level is
downregulated in patients with acromegaly compared to
healthy adults. This downregulation is more pronounced
in patients with acromegaly inadequately controlled with
SAA therapy. These results suggest that miR-29c-3p may be
a target miRNA for acromegaly. We believe that this study
will shed light on future studies.
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